Q3: Non-GAAP Net Income $1.9 Million; EBITDA Margin of 34.6%; EBITDA of $2.2 Million; Non-GAAP EPS $0.39 9 Months: Non-GAAP ...

Revenue Guidance -- Management reiterated full-year fiscal 2025 revenue guidance of $26 million to $30 million and set Q4 ...

A shattered kingdom with you as the chosen one to bring it back to its glory while redeeming corrupted maidens and evolving them as they fight for you—what’s not to love in this game? All that’s left ...

And except as required by law, STRATA Skin Sciences disclaims any obligation to publicly update or revise any information to ...

STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of ...

Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today ...

Q3 2025 Earnings Call Transcript November 13, 2025 Bionano Genomics, Inc. beats earnings expectations. Reported EPS is ...

Q3 2025 Earnings Call Transcript November 11, 2025 Operator: Good morning, everyone, and welcome to the Xtant Medical ...

Bionano Genomics, Inc. ( BNGO) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Good day, and welcome to the Bionano Third Quarter 2025 Earnings Conference Call. Today's conference is being ...

Baron Fifth Avenue Growth Fund gained 5.7% during the quarter but lagged its benchmarks, the Russell 1000 Growth Index and the S&P 500 Index. Read more here.

I. INTRODUCTION - Brand license agreements can drive business growth and brand recognition. By granting rights to use, develop, ...

Generic SaaS is losing steam. In 2025, the fastest-growing companies are those that pick their lane and build for one ...